Discontinuation of glucagon-like peptide-1 receptor agonists
Treating rest like a prescription, not an afterthought, protects healing, mental health and long-term well-being for you and your baby
Therefore, it is not advisable to use Semaglutide GLP-1 for weight loss unless you meet the approved criteria and are under the care of a licensed healthcare professional who can evaluate your health history, monitor your progress, and determine if the treatment is safe and appropriate for your needs
Semaglutide is administered subcutaneously (under the skin, not into muscle) once weekly, typically in the abdomen, thigh, or upper arm
Dysesthesia occurred more frequently in retatrutide-treated participants but was generally mild and rarely led to treatment discontinuation